{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:18:49Z","timestamp":1790731129876,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T00:00:00Z","timestamp":1382400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Appendiceal adenocarcinomas (AAs) are rare and this has limited their molecular understanding. The purpose of our study was to characterize the molecular profile of AA and explore the role of targeted therapy against cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>We performed a retrospective review of 607 patients with AA at a single institution. A total of 149 patients underwent molecular testing for at least one of the following: activating mutations in KRAS, BRAF, cKIT, EGFR, or PI3K; protein expression of c-KIT or COX-2; or microsatellite instability (MSI) status by immunohistochemistry. Kaplan-Meier product limit method and log-rank test were used to estimate overall survival (OS) and to determine associations among OS, COX-2 expression, KRAS mutations, and other characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Age, grade, stage, signet ring cells, mucinous histology, and completeness of cytoreduction score correlated with survival outcomes. COX-2 expression, KRAS, PI3K, and BRAF mutations were seen in 61%, 55%, 17%, and 4% of patients, respectively. High MSI was seen in 6% of patients. KRAS mutation was strongly associated with well differentiated or moderately differentiated AA (p &amp;lt; .01). COX-2 expression (p = .33) and the presence of KRAS mutation (p = .91) had no impact on OS. The use of celecoxib in patients whose tumors expressed COX-2 (p = .84) and the use of cetuximab or panitumumab in patients with KRAS wild-type tumors (p = .83) also had no impact on OS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>In this cohort, we demonstrated that COX-2 expression and KRAS mutations were frequently seen in AA, although neither exhibited any prognostic significance. MSI was infrequent in AA. Targeted therapy against COX-2 and EGFR appeared to provide no clinical benefit. Well and moderately differentiated AA were molecularly distinct from poorly differentiated AA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2013-0186","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T06:11:08Z","timestamp":1382508668000},"page":"1270-1277","source":"Crossref","is-referenced-by-count":46,"title":["Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas"],"prefix":"10.1093","volume":"18","author":[{"given":"Kanwal P.S.","family":"Raghav","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Houston Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya V.","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed M.A.","family":"Kazmi","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Houston Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianxiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Computational Biology, Houston Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Houston Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Taggart","sequence":"additional","affiliation":[{"name":"Department of Pathology, Houston Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Fournier","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston Texas, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Royal","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston Texas, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston Texas, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Houston Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Houston Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Houston Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,10,22]]},"reference":[{"key":"2021122308441725600_B1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02236899","article-title":"Appendiceal tumors: Retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies","volume":"41","author":"Connor","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"2021122308441725600_B2","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1002\/cncr.10589","article-title":"Primary malignant neoplasms of the appendix: A population-based study from the surveillance, epidemiology and end-results program, 1973\u20131998","volume":"94","author":"McCusker","year":"2002","journal-title":"Cancer"},{"key":"2021122308441725600_B3","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1245\/s10434-012-2238-1","article-title":"Importance of histologic subtype in the staging of appendiceal tumors","volume":"19","author":"Turaga","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2021122308441725600_B4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ejso.2010.05.025","article-title":"Primary appendiceal carcinoma\u2013epidemiology, surgery and survival: Results of a German multi-center study","volume":"36","author":"Benedix","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"2021122308441725600_B5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00000478-200308000-00006","article-title":"Appendiceal mucinous neoplasms: A clinicopathologic analysis of 107 cases","volume":"27","author":"Misdraji","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"2021122308441725600_B6","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jamcollsurg.2011.02.002","article-title":"Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity?","volume":"212","author":"Raghav","year":"2011","journal-title":"J Am Coll Surg"},{"key":"2021122308441725600_B7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000658-199401000-00009","article-title":"The natural history of surgically treated primary adenocarcinoma of the appendix","volume":"219","author":"Nitecki","year":"1994","journal-title":"Ann Surg"},{"key":"2021122308441725600_B8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s10434-006-9708-2","article-title":"Appendiceal neoplasms with peritoneal dissemination: Outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy","volume":"13","author":"Stewart","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"2021122308441725600_B9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","article-title":"New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?","volume":"7","author":"Sugarbaker","year":"2006","journal-title":"Lancet Oncol"},{"key":"2021122308441725600_B10","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO;2-T","article-title":"American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group","volume":"88","author":"Compton","year":"2000","journal-title":"Cancer"},{"key":"2021122308441725600_B11","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jama.282.13.1254","article-title":"The relationship between cyclooxygenase-2 expression and colorectal cancer","volume":"282","author":"Sheehan","year":"1999","journal-title":"JAMA"},{"key":"2021122308441725600_B12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM198809013190901","article-title":"Genetic alterations during colorectal-tumor development","volume":"319","author":"Vogelstein","year":"1988","journal-title":"N Engl J Med"},{"key":"2021122308441725600_B13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jnci\/90.9.675","article-title":"Kirsten ras mutations in patients with colorectal cancer: The multicenter \u201cRASCAL\u201d study","volume":"90","author":"Andreyev","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2021122308441725600_B14","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308441725600_B15","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308441725600_B16","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1200\/JCO.2009.21.9170","article-title":"American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy","volume":"27","author":"Allegra","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308441725600_B17","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","article-title":"Celecoxib for the prevention of colorectal adenomatous polyps","volume":"355","author":"Arber","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122308441725600_B18","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI119400","article-title":"Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2","volume":"99","author":"Sheng","year":"1997","journal-title":"J Clin Invest"},{"key":"2021122308441725600_B19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1179\/joc.2007.19.4.451","article-title":"Mucinous cancer of the appendix: Challenges in diagnosis and treatment","volume":"19","author":"Andreopoulou","year":"2007","journal-title":"J Chemother"},{"issue":"18S","key":"2021122308441725600_B20","doi-asserted-by":"crossref","first-page":"14020","DOI":"10.1200\/jco.2006.24.18_suppl.14020","article-title":"Phase II study of cetuximab in mucinous peritoneal carcinomatosis","volume":"24","author":"Andreopoulou","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308441725600_B21","volume-title":"AJCC (American Joint Committee on Cancer) Cancer Staging Manual","author":"Edge","year":"2010","edition":"7th ed"},{"key":"2021122308441725600_B22","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"2021122308441725600_B23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"2021122308441725600_B24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jss.2012.10.053","article-title":"Kras mutations and p53 overexpression in pseudomyxoma peritonei: Association with phenotype and prognosis","volume":"180","author":"Shetty","year":"2013","journal-title":"J Surg Res"},{"key":"2021122308441725600_B25","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3109\/00365521.2011.565070","article-title":"Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix","volume":"46","author":"Zauber","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"2021122308441725600_B26","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1097\/SLA.0b013e318269d680","article-title":"Improving the AJCC\/TNM staging for adenocarcinomas of the appendix: The prognostic impact of histological grade","volume":"257","author":"Overman","year":"2013","journal-title":"Ann Surg"},{"issue":"4S","key":"2021122308441725600_B27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1200\/jco.2013.31.4_suppl.199","article-title":"The natural history and role of surgical cytoreduction and systemic chemotherapy in high-grade mucinous adenocarcinomas of the appendix","volume":"31","author":"Overman","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122308441725600_B28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrclinonc.2009.237","article-title":"Microsatellite instability in colorectal cancer-the stable evidence","volume":"7","author":"Vilar","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122308441725600_B29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc2645","article-title":"Genetic prognostic and predictive markers in colorectal cancer","volume":"9","author":"Walther","year":"2009","journal-title":"Nat Rev Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2013-0186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2013-0186","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/12\/1270\/41857912\/oncolo_18_12_1270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/12\/1270\/41857912\/oncolo_18_12_1270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T01:21:24Z","timestamp":1640308884000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/12\/1270\/6399157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,22]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,10,22]]},"published-print":{"date-parts":[[2013,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2013-0186","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,12,1]]},"published":{"date-parts":[[2013,10,22]]}}}